Other Comprehensive Income (Loss), Net of Tax [Abstract] Other comprehensive income Other Comprehensive Income [Text Block] Other Comprehensive Income [Text Block] Goodwill and Intangible Assets Disclosure [Abstract] Estimated amortization of intangible assets, subsequent years Estimated Amortization of Intangible Assets, Number of Subsequent Periods Estimated Amortization of Intangible Assets, Number of Subsequent Periods 2012 Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months 2013 Finite-Lived Intangible Assets, Amortization Expense, Year Two 2014 Finite-Lived Intangible Assets, Amortization Expense, Year Three 2015 Finite-Lived Intangible Assets, Amortization Expense, Year Four 2016 Finite-Lived Intangible Assets, Amortization Expense, Year Five Debt Instruments [Abstract] Line of Credit Facility [Table] Line of Credit Facility [Table] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] LIBOR Rate [Member] Libor Rate [Member] Libor Rate [Member] Alternate Base Rate [Member] Alternate Base Rate [Member] Alternate Base Rate [Member] Range [Axis] Range [Axis] Range [Domain] Range [Domain] Minimum [Member] Minimum [Member] Maximum [Member] Maximum [Member] Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Term Loan A Due 2016 [Member] Term Loan Due Two Thousand Sixteen [Member] Term Loan A Due Two Thousand Sixteen [Member]. Term Loan B Due 2018 [Member] Term Loan B Due Two Thousand Eighteen [Member] Term Loan B Due Two Thousand Eighteen [Member]. Line of Credit Facility [Axis] Lender Name [Axis] Line of Credit Facility, Lender [Domain] Line of Credit Facility, Lender [Domain] Revolving Credit Facility And Together With Term Loan Facilities2011 Credit Facility [Member] Revolving Credit Facility And Together With Term Loan Facilities2011 Credit Facility [Member] Revolving Credit Facility And, Together With The Term Loan Facilities, The 2011 Credit Facility [Member]. 2011 Credit Facility [Member] Two Thousand Eleven Credit Facility [Member] Two Thousand Eleven Credit Facility [Member]. Credit Facilities [Member] Credit Facility [Member] Credit Facility [Member] Line of Credit Facility [Line Items] Line of Credit Facility [Line Items] Revolving credit facility, borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Additional revolving or term loan commitments Line of Credit Facility, Increase, Additional Borrowings Additional Revolving or Term Loan Commitments Additional Revolving or Term Loan Commitments Additional Revolving or Term Loan Commitments Debt Instrument, Description of Variable Rate Basis Debt Instrument, Description of Variable Rate Basis Margin rate over base rate Debt Instrument, Basis Spread on Variable Rate LIBOR margin Libor Margin Libor Margin Commitment fee basis points Line Of Credit Facility Commitment Fee Basis Points Line of credit facility commitment fee basis points. Payments of financing costs Payments of Financing Costs Cost paid to investment bankers Amount Of Cost Paid To Investment Bankers Amount of cost paid to investment bankers. Financing costs deferred and amortized to interest expense Amortization of Financing Costs Write off of Deferred Debt Issuance Cost Write off of Deferred Debt Issuance Cost Prepayment of term loan facility Prepayment Of Term Loan Facility Prepayment of term loan facility. Unamortized finance costs written off Unamortized Finance Cost Written Off Unamortized finance cost written off. Interest expense Interest Expense, Debt Commitments and Contingencies Disclosure [Abstract] Commitments and contingencies Commitments and Contingencies Disclosure [Text Block] Debt Debt Disclosure [Text Block] Fair Value Disclosures [Abstract] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Extinguishment of Debt [Axis] Extinguishment of Debt [Axis] Extinguishment of Debt, Type [Domain] Extinguishment of Debt, Type [Domain] Acquisition-related contingent consideration [Member] Acquisition Related Contingent Consideration [Member] Acquisition-Related Contingent Consideration [Member] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Beginning Balance Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value Amounts (acquired) sold/ or (issued) settled, net Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases, Sales, Issues, Settlements Transfers in and/or (out) of Level 3 Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net Changes in fair value recorded in earnings Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Ending Balance Schedule of tax effects allocated to each component of other comprehensive income Schedule of Amounts Recognized in Other Comprehensive Income (Loss) [Table Text Block] Schedule of Available-for-sale Securities [Table] Schedule of Available-for-sale Securities [Table] Schedule of Investment Income, Reported Amounts, by Category [Axis] Schedule of Investment Income, Reported Amounts, by Category [Axis] Investment Income, Categories [Domain] Investment Income, Categories [Domain] Total included in cash and cash equivalents [Member] Cash and Cash Equivalents [Member] Long-term available-for-sale securities [Member] Long Term Available For Sale Securities [Member] Long-Term Available-for-Sale Securities [Member] Schedule of Trading Securities and Other Trading Assets, Major Types of Trading Securities and Assets [Axis] Major Types of Debt and Equity Securities [Axis] Major Types of Trading Securities and Assets [Domain] Major Types of Debt and Equity Securities [Domain] Money market funds [Member] Money Market Funds [Member] Auction-rate securities [Member] Auction Rate Securities [Member] Equity securities [Member] Equity Securities [Member] Schedule of Available-for-sale Securities [Line Items] Schedule of Available-for-sale Securities [Line Items] Amortized Cost Available-for-sale Securities, Amortized Cost Basis Gross Unrealized Gains Available-for-sale Securities, Gross Unrealized Gains Gross Unrealized (Losses) Available-for-sale Securities, Gross Unrealized Losses Fair Value Available-for-sale Securities, Fair Value Disclosure Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments And Hedging Activities Derivative Instruments and Hedging Activities Disclosure [Text Block] Commitments And Contingencies [Table] Commitments And Contingencies [Table] Commitments And Contingencies [Table] Measurement Frequency [Axis] Measurement Frequency [Axis] Fair Value, Measurement Frequency [Domain] Fair Value, Measurement Frequency [Domain] Fair value, measurements, nonrecurring [Member] Fair Value, Measurements, Nonrecurring [Member] Indefinite-lived Intangible Assets by Major Class [Axis] Indefinite-lived Intangible Assets by Major Class [Axis] Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-lived Intangible Assets, Major Class Name [Domain] AMS [Member] Unclassified Indefinite-lived Intangible Assets [Member] Litigation Case [Axis] Litigation Case [Axis] Litigation Case Type [Domain] Litigation Case Type [Domain] State of Louisiana v. Abbott Laboratories, Inc [Member] State of Louisiana v. Abbott Laboratories, Inc [Member] State of Louisiana v. Abbott Laboratories, Inc [Member] State of Texas v. Abbott Laboratories, Inc [Member] State of Texas v. Abbott Laboratories, Inc [Member] State of Texas v. Abbott Laboratories, Inc [Member] Scenario [Axis] Scenario [Axis] Scenario, Unspecified [Domain] Scenario, Unspecified [Domain] Previously reported [Member] Scenario, Previously Reported [Member] As adjusted [Member] Scenario, Adjustment [Member] Amended amount [Member] Scenario, Actual [Member] 2013 Payments [Member] 2013 Payments [Member] 2013 Payments [Member] 2014 Payments, pending FDA approval [Member] 2014 Payments, Pending FDA Approval [Member] 2014 Payments, Pending FDA Approval [Member] 2015 Payments, pending FDA approval [Member] 2015 Payments, Pending FDA Approval [Member] 2015 Payments, Pending FDA Approval [Member] Loss Contingencies by Nature of Contingency [Axis] Loss Contingency Nature [Axis] Loss Contingency, Nature [Domain] Loss Contingency, Nature [Domain] MCP cases [Member] Mcp Cases [Member] MCP Cases [Member] Propoxyphene cases [Member] Propoxyphene Cases [Member] Propoxyphene Cases [Member] Vaginal mesh cases [Member] Vaginal Mesh Cases [Member] Vaginal Mesh Cases [Member] Purchase Commitment, Excluding Long-term Commitment [Axis] Purchase Commitment, Excluding Long-term Commitment [Axis] Purchase Commitment, Excluding Long-term Commitment [Domain] Purchase Commitment, Excluding Long-term Commitment [Domain] Manufacturing agreement [Member] Manufacturing Agreement [Member] Manufacturing Agreement [Member] Voltaren Gel Agreement Extending Through June Two Thousand Eleven [Member] [Member] Voltaren Gel Agreement Extending Through June Two Thousand Eleven [Member] Voltaren Gel Agreement Extending Through June Two Thousand Eleven Ventiv agreement [Member] Ventiv Agreement [Member] Ventiv Agreement [Member] Voltaren gel agreement extending through June 30, 2012 [Member] Voltaren Gel Agreement Extending Through June Two Thousand Twelve [Member] Voltaren Gel Agreement Extending Through June 2012 [Member] Paragraph IV certification on frova [Member] Paragraph Four Certification On Frova [Member] Paragraph Four Certification On Frova [Member] Voltaren Gel Agreement Extending Through June Two Thousand Thirteen [Member] [Member] Voltaren Gel Agreement Extending Through June Two Thousand Thirteen [Member] Voltaren Gel Agreement Extending Through June Two Thousand Thirteen Supply Commitment [Axis] Supply Commitment [Axis] Supply Commitment Arrangement [Domain] Supply Commitment Arrangement [Domain] Sales representatives [Member] Sales Representatives [Member] Sales Representatives [Member] District managers [Member] District Managers [Member] District Managers [Member] Project manager [Member] Project Manager [Member] Project Manager [Member] Trainer [Member] Trainer [Member] Trainer [Member] National sales director [Member] National Sales Director [Member] National Sales Director [Member] Legal Entity [Axis] Legal Entity [Axis] Entity [Domain] Entity [Domain] Novartis Consumer Health, Inc. [Member] Novartis Consumer Health Inc [Member] Novartis Consumer Health Inc [Member] Teikoku Seiyaku Co., Ltd. [Member] Teikoku Seiyaku Co Ltd [Member] Teikoku Seiyaku Co Ltd [Member] Mallinckrodt Inc. [Member] Mallinckrodt Inc [Member] Mallinckrodt Inc [Member] Noramco, Inc. [Member] Noramco Inc [Member] Noramco, Inc [Member] Grunenthal Agreement [Member] Grunenthal Agreement [Member] Grunenthal Agreement [Member] Sharp Corporation [Member] Sharp Corporation [Member] Sharp Corporation [Member] UPS Supply Chain Solutions [Member] UPS Supply Chain Solutions [Member] UPS Supply Chain Solutions [Member] Watson Laboratories, Inc [Member] Watson Laboratories, Inc [Member] Watson Laboratories, Inc [Member] Impax Laboratories, Inc. [Member] Impax Laboratories Inc [Member] Impax Laboratories, Inc. [Member] Commitments And Contingencies [Line Items] Commitments And Contingencies [Line Items] Commitments And Contingencies [Line Items] Purchase commitment term (in years) Long-term Purchase Commitment, Period Long-term purchase commitment, period. Purchase commitment, renewal term (in years) Long-term purchase commitment, renewal period Long-term purchase commitment, renewal period. Required minimum purchase Long-term Purchase Commitment, Amount Required minimum spending percentage of prior year sales Long Term Purchase Commitment Percentage Long-term purchase commitment Percentage. Amounts incurred by Endo for A&P Expenditures Marketing and Advertising Expense Japanese facilities for commercial sale in the United States Japanese Facilities For Commercial Sale in the United States Japanese Facilities For Commercial Sale in the United States Termination of agreement notice period (days) Termination Of Agreement Notice Period Termination Of Agreement Notice Period Termination of agreement written notice after expiration date, (in days) Termination Of Agreement Written Notice After Expiration Date Termination Of Agreement Written Notice After Expiration Date Percentage of royalty rate of net sales Percentage Of Royalty Rate Of Net Sales Percentage of royalty rate of net sales. Payments for royalties Payments for Royalties Royalty payable Accrued Royalties Wholesaler price discount percentage Price Discount Percentage Price Discount Percentage Noramco agreement term (years) Long-term Purchase Commitment, Term Long-term Purchase Commitment, Term Automatic renewal provision for unlimited successive periods, (in years) Automatic renewal provision for unlimited successive periods Automatic renewal provision for unlimited successive periods, in years. Sales and promotional services employees Sales And Promotional Services Employees Sales and promotional services employees. Expenses incurred with respect to Ventiv under the Ventiv Agreement Costs and Expenses, Related Party Initial term of agreement extended date, UPS Supply Chain Solutions Initial Term Of Agreement, Extended Date Initial term of agreement, extended date. Termination costs maximum, UPS Supply Chain Solutions Termination Cost Maximum Termination Cost Maximum Range of possible loss, minimum Loss Contingency, Range of Possible Loss, Minimum Litigation settlement expense Litigation Settlement, Expense Settlement agreement terms Loss Contingency, Settlement Agreement, Terms Percentage of royalty rate of gross sales (percent) Percentage Of Royalty Rate Of Gross Sales Percentage Of Royalty Rate Of Gross Sales Other Commitment, Due In Second Year, Periodic Payment Other Commitment, Due In Second Year, Periodic Payment Other Commitment, Due In Second Year, Periodic Payment Other commitment, due in second year Other Commitment, Due in Second Year Other commitment, due In third year Other Commitment, Due In Third Year, Periodic Payment Other Commitment, Due In Third Year, Periodic Payment Other commitment, due in third year Other Commitment, Due in Third Year Other Commitment, Due In Fourth Year, Periodic Payment Other Commitment, Due In Fourth Year, Periodic Payment Other Commitment, Due In Fourth Year, Periodic Payment Other commitment, due in fourth year Other Commitment, Due in Fourth Year Rebate percent Litigation Settlement, Rebate of Cost, Percent Litigation Settlement, Rebate of Cost, Percent Estimated litigation liability Estimated Litigation Liability Gain (loss) related to litigation settlement Gain (Loss) Related to Litigation Settlement Discount rate Fair Value Inputs, Discount Rate Increase (decrease) in accounts payable Increase (Decrease) in Accounts Payable Accounts payable Accounts Payable, Current Patents expiration date Patents Expiration Date Patents expiration date. Overall liability cap for all claims arising out of or related to acquisition Overall Liability Cap For All Claims Arising Out Of Or Related To Acquisitions Overall liability cap for all claims arising out of or related to acquisitions. Pending claims, number Loss Contingency, Pending Claims, Number Loss Contingency, Cases on Appeal, Number Loss Contingency, Cases on Appeal, Number Loss Contingency, Cases on Appeal, Number New headquarters office space, square feet New Headquarters Office Space New headquarters office space. Term of triple net lease (years) Term of Triple Net Lease Term of Triple Net Lease in years Number of triple net lease renewal options Number Of Triple Net Lease Renewal Options Number of triple net lease renewal options. Additional lease term period (months) Additional Lease Term Period Additional lease term period. Monthly lease rate for the initial year, 2013 Operating Leases, Future Minimum Payments, Due in Two Years Percentage increase in lease rate Percentage Increase In Lease Rate Percentage increase in lease rate. Lease initial term Description Of Lessee Leasing Arrangements, Operating Leases, Initial Term Description Of Lessee Leasing Arrangements, Operating Leases, Initial Term Additional office space, square feet Additional Office Space Additional office space. Tenant improvement allowance per square foot Payments for Leasing Costs, Commissions, and Tenant Improvements Capitalized property, plant and equipment related to corporate headquarters lease Increase (Decrease) in Lease Acquisition Costs Corporate headquarter lease liability recorded Capital Lease Obligations Loss Contingency, Lawsuit Filing Period Loss Contingency, Lawsuit Filing Period Loss Contingency, Lawsuit Filing Period Loss Contingency, Stay Of Approval Period, Hatch-Waxman Act Loss Contingency, Stay Of Approval Period, Hatch-Waxman Act Loss Contingency, Stay Of Approval Period, Hatch-Waxman Act Litigation reserve, change in fair value Litigation Reserve, Change in Fair Value Litigation Reserve, Change in Fair Value Patent litigation settlement liability Litigation Reserve, Fair Value Litigation Reserve, Fair Value Recent Accounting Pronouncements [Abstract] Recent Accounting Pronouncements [Abstract] Recent accounting pronouncements Recent Accounting Pronouncements [Text Block] Recent Accounting Pronouncements [Text Block] Statement of Cash Flows [Abstract] OPERATING ACTIVITIES [Abstract] Net Cash Provided by (Used in) Operating Activities [Abstract] CONSOLIDATED NET (LOSS) INCOME Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Adjustments to reconcile consolidated net (loss) income to net cash [provided by] operating activities: [Abstract] Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Depreciation and amortization Depreciation, Depletion and Amortization, Nonproduction Stock-based compensation Share-based Compensation Amortization of debt issuance costs and premium / discount Amortization of Financing Costs and Discounts Selling, general and administrative expenses paid in shares of common stock Common Stock Associated With General And Administrative Expense Shares of common stock issued in lieu of cash for Director fees. Deferred income taxes Deferred Income Taxes and Tax Credits Gain (loss) on disposal of property, plant and equipment Gain (Loss) on Sale of Property Plant Equipment Change in fair value of acquisition-related contingent consideration Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Loss on extinguishment of debt Extinguishment of Debt, Gain (Loss), Net of Tax Asset impairment charges Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) Changes in assets and liabilities which provided (used) cash: [Abstract] Increase (Decrease) in Operating Capital [Abstract] Accounts receivable Increase (Decrease) in Accounts Receivable Inventories Increase (Decrease) in Inventories Prepaid and other assets Increase (Decrease) in Prepaid Expense and Other Assets Accounts payable Accrued expenses Increase (Decrease) in Accrued Liabilities Other liabilities Increase (Decrease) in Other Operating Liabilities Income taxes payable/receivable Increase (Decrease) in Income Taxes Receivable Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities INVESTING ACTIVITIES: Net Cash Provided by (Used in) Investing Activities [Abstract] Purchases of property, plant and equipment Payments to Acquire Property, Plant, and Equipment Proceeds from sale of property, plant and equipment Proceeds from Sale of Property, Plant, and Equipment Acquisitions, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Proceeds from investments Proceeds From Investing Activities Proceeds From Investing Activities Purchases of investments Payments For Investing Activities Payments For Investing Activities Other investments Payments to Acquire Other Investments Payment on contingent consideration Payment On Contingent Consideration Payment On Contingent Consideration License fees License Costs Proceeds from sale of business Proceeds from Divestiture of Businesses Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities FINANCING ACTIVITIES: Net Cash Provided by (Used in) Financing Activities [Abstract] Capital lease obligation repayments Repayments of Long-term Capital Lease Obligations Proceeds from issuance of 2019 and 2022 Notes Debt Instrument, Periodic Payment, Principal Proceeds from issuance of Term Loans Proceeds from Issuance of Debt Proceeds from other indebtedness Proceeds from Other Debt Principal payments on Term Loans Repayments of Lines of Credit Payment on AMS Convertible Notes Repayments of Convertible Debt Principal payments on other indebtedness Repayments of Debt Deferred financing fees Tax benefits of stock awards Excess Tax Benefit (Tax Deficiency) from Share-based Compensation, Financing Activities Exercise of Endo Health Solutions Inc. stock options Proceeds from Stock Options Exercised Purchase of common stock Payments for Repurchase of Common Stock Issuance of common stock from treasury Proceeds from Sale of Treasury Stock Distributions to noncontrolling interests Payments of Ordinary Dividends, Noncontrolling Interest Buy-out of noncontrolling interests, net of contributions Payments to Noncontrolling Interests Net cash provided by (used in) financing activities Net Cash Provided by (Used in) Financing Activities Effect of foreign exchange rate Effect of Exchange Rate on Cash and Cash Equivalents NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS Cash and Cash Equivalents, Period Increase (Decrease) CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD Cash and Cash Equivalents, at Carrying Value CASH AND CASH EQUIVALENTS, END OF PERIOD SUPPLEMENTAL INFORMATION [Abstract] Supplemental Cash Flow Information [Abstract] Cash paid for interest Interest Paid Cash paid for income taxes Income Taxes Paid SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES [Abstract] Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Purchases of property, plant and equipment financed by capital leases Capital Lease Obligations Incurred Accrual for purchases of property, plant and equipment Capital Expenditures Incurred but Not yet Paid Subsequent Events [Abstract] Subsequent Events Subsequent Events [Text Block] Derivative [Table] Derivative [Table] Fair Value by Asset Class [Axis] Asset Class [Axis] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, by Asset Class [Domain] Fair Value by Asset Class [Domain] Prepaid expenses and other current assets [Member] Prepaid expenses and other current assets [Member] Prepaid expenses and other current assets [Member] Accrued Expenses [Member] Accrued Expenses [Member] Accrued Expenses [Member] Hedging Designation [Axis] Hedging Designation [Axis] Hedging Designation [Domain] Hedging Designation [Domain] Designated As Cash Flow Accounting Hedges [Member] Designated as Hedging Instrument [Member] Not Designated As Accounting Hedges [Member] Not Designated as Hedging Instrument [Member] Derivative [Line Items] Derivative [Line Items] Remaining maturity Derivative, Remaining Maturity Notional amount of foreign currency exchange forward contracts Notional Amount of Foreign Currency Derivatives Fair value of derivatives designated for hedge accounting Derivative Instruments in Hedges, Assets, at Fair Value Reclassification from other comprehensive loss into earnings Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months Amount of gain (loss) from derivative contracts Derivative, Gain (Loss) on Derivative, Net Fair Value, Liabilities Measured on Recurring Basis, Disclosure Items [Axis] Fair Value, Hierarchy [Axis] Fair Value, Liabilities Measured on Recurring Basis, Disclosure Items [Domain] Fair Value, Measurements, Fair Value Hierarchy [Domain] Significant unobservable inputs (Level 3) [Member] Fair Value, Inputs, Level 3 [Member] Beginning balance Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value Securities sold or redeemed Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Securities Sold or Redeemed Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Securities Sold or Redeemed Securities purchase or acquired Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Securities Purchased or Acquired Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Securities Purchased or Acquired Transfers in and/or (out) of Level 3 Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net Changes in fair value recorded in earnings Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings Unrealized gains included in other comprehensive income Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Other Comprehensive Income (Loss) Ending balance Stockholders' Equity Note [Abstract] Stockholders' equity Stockholders' Equity Note Disclosure [Text Block] Other Cost and Expense Disclosure, Operating [Abstract] Cost of net pharmaceutical product sales Cost of Goods and Services Sold Cost of devices revenues Cost Of Devices Revenues Cost of devices revenues. Cost of service and other revenues Other Cost of Operating Revenue Total Cost of revenues Cost of Revenue Statement of Financial Position [Abstract] ASSETS Assets [Abstract] CURRENT ASSETS: Assets, Current [Abstract] Cash and cash equivalents Accounts receivable, net Accounts Receivable, Net, Current Inventories, net Inventory, Net Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Income taxes receivable Income Taxes Receivable, Current Deferred income taxes Deferred Tax Assets, Net of Valuation Allowance, Current Total current assets Assets, Current MARKETABLE SECURITIES Marketable Securities, Noncurrent PROPERTY, PLANT AND EQUIPMENT, NET Property, Plant and Equipment, Net GOODWILL Goodwill OTHER INTANGIBLES, NET Intangible Assets, Net (Excluding Goodwill) OTHER ASSETS Other Assets, Noncurrent TOTAL ASSETS Assets LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities and Equity [Abstract] CURRENT LIABILITIES: Liabilities, Current [Abstract] Accounts payable Accrued expenses Accrued Liabilities, Current Current portion of long-term debt Long-term Debt, Current Maturities Acquisition-related contingent consideration Business Acquisition, Contingent Consideration, Potential Cash Payment Income taxes payable Accrued Income Taxes, Current Total current liabilities Liabilities, Current DEFERRED INCOME TAXES Deferred Tax Liabilities, Net, Noncurrent ACQUISITION-RELATED CONTINGENT CONSIDERATION Business Acquisition, Contingent Consideration, at Fair Value, Noncurrent LONG-TERM DEBT, LESS CURRENT PORTION, NET Long-term Debt, Excluding Current Maturities OTHER LIABILITIES Other Liabilities, Noncurrent COMMITMENTS AND CONTINGENCIES (NOTE 12) Commitments and Contingencies STOCKHOLDERS' EQUITY: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Preferred Stock, $0.01 par value; 40,000,000 shares authorized; none issued Preferred Stock, Value, Issued Common Stock, $0.01 par value; 350,000,000 shares authorized; 139,673,311 and 138,337,002 shares issued; 113,991,489 and 117,158,880 shares outstanding at September 30, 2012 and December 31, 2011, respectively Common Stock, Value, Issued Additional paid-in capital Additional Paid in Capital Retained earnings Retained Earnings (Accumulated Deficit) Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Treasury stock, 25,681,822 and 21,178,122 shares at September 30, 2012 and December 31, 2011, respectively Treasury Stock, Value Total Endo Health Solutions Inc. stockholders' equity Stockholders' Equity Attributable to Parent Noncontrolling interests Stockholders' Equity Attributable to Noncontrolling Interest Total stockholders' equity Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities and Equity Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] 3.25% AMS Convertible Notes Due 2036 [Member] Three Point Two Five Ams Convertible Notes Due Two Thousand Thirty Six [Member] Three Point Two Five AMS Convertible Notes Due Two Thousand Thirty Six [Member] 4.00% AMS Convertible Notes Due 2041 [Member] Four Point Zero Zero Percent Ams Convertible Notes Due Two Thousand Forty One [Member] Four Point Zero Zero Percent AMS Convertible Notes Due Two Thousand Forty One [Member] AMS Notes [Member] Ams Notes [Member] AMS Notes [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Notes, interest rate Debt Instrument, Interest Rate, Stated Percentage Debt Instrument Maturity Year Debt Instrument Maturity Year Debt instrument maturity year. Amount paid for redemption Amount Paid for Redemption Of Debt Instrument Convertible Amount paid for redemption of debt instrument convertible. Convertible Notes, principal amount convertible Debt Conversion, Original Debt, Amount Stated conversion premium Debt Instrument convertible Debt Stated Conversion Premium Debt instrument convertible debt stated conversion premium. Remaining principal amount, maximum Remaining Principal Premiums Remaining Principal Premiums Interest expense Debt Instrument, Convertible, Interest Expense Segment Reporting [Abstract] Segment results Segment Reporting Disclosure [Text Block] Summary of activity under stock incentive plans Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block] Stock option assumption Stock Option Assumption [Text Block] Stock Option Assumption [Text Block] Summary of restricted stock units activity Summary of restricted stock units [Text Block] Summary of restricted stock units [Text Block] Summary of restricted stock activity Summary Of Restricted Stock Awards [Text Block] Summary Of Restricted Stock Awards [Text Block] Schedule of changes in stockholders' equity Schedule Of Changes In Stockholders' Equity [Table Text Block] Schedule Of Changes In Stockholders' Equity [Table Text Block] Business Combination, Description [Abstract] Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table] Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table] Customer relationships [Member] Customer Relationships [Member] Developed technology [Member] Developed Technology Rights [Member] Tradenames [Member] Trade Names [Member] In process research & development [Member] In Process Resear In Process Research And Development Member Ch And Development [Member] In Process Research and Development [Member]. Business Acquisition [Axis] Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] AMS [Member] Ams [Member] AMS [Member] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Men's health [Member] Mens Health [Member] Mens Health [Member] Women's health [Member] Womens Health [Member] Womens Health [Member] BPH [Member] Benign Prostatic Hyperplasia [Member] Benign Prostatic Hyperplasia [Member] AMS [Member] Ams Tradename [Member] AMS Tradename [Member] GreenLight [Member] Green Light Tradename [Member] Green Light Tradename [Member] Oracle [Member] Oracle [Member] Oracle [Member] Genesis [Member] Genesis [Member] Genesis [Member] TOPAS [Member] Topas [Member] TOPAS [Member] Other [Member] Other Credit Derivatives [Member] Acquired Finite-Lived Intangible Assets [Line Items] Acquired Finite-Lived Intangible Assets [Line Items] Valuation Acquired Finite-lived Intangible Asset, Amount Amortization Period (in years) Acquired Finite-lived Intangible Assets, Weighted Average Useful Life Asset impairment charges Asset Impairment Charges Income Tax Disclosure [Abstract] Effective income tax rate on earnings from continuing operations before income taxes Effective Income Tax Rate, Continuing Operations Increase in the effective income tax rate Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate Income tax benefit, resulting from lapse of applicable statute of limitations Income Tax Benefit, Resulting from Lapse of Applicable Statute of Limitations Income Tax Benefit, Resulting from Lapse of Applicable Statute of Limitations Income tax expense (benefit) Income Tax Expense (Benefit) Valuation allowance Deferred Tax Assets, Valuation Allowance Adjustment to income tax expense Adjustment To Income Tax Expense (Benefit) Adjustment To Income Tax Expense (Benefit) Benefit for a prior period adjustment Valuation Allowance, Deferred Tax Asset, Change in Amount Inventory, Net [Abstract] Schedule of inventories Schedule of Inventory, Current [Table Text Block] Earnings Per Share [Abstract] Net (Loss) Income Per Share Earnings Per Share [Text Block] Cost Of Revenues Cost of Revenues Disclosure Text Block Cost of Revenues Disclosure Text Block Indefinite-lived Intangible Assets Acquired as Part of Business Combination [Table] Indefinite-lived Intangible Assets Acquired as Part of Business Combination [Table] Acquired Indefinite-lived Intangible Assets [Line Items] Acquired Indefinite-lived Intangible Assets [Line Items] Bank fees Business Combination Acquisition Related Costs Investment Banking Fees Business Combination Acquisition Related Costs Investment Banking Fees Legal, separation, integration, and other costs Business Acquisition Cost Of Acquired Entity Transaction Costs Legal and other costs Business Acquisition Cost Of Acquired Entity Transaction Costs Legal and other costs Total Business Combination, Acquisition Related Costs Preferred Stock, par value (usd per share) Preferred Stock, Par or Stated Value Per Share Preferred Stock, shares authorized Preferred Stock, Shares Authorized Preferred Stock, shares issued Preferred Stock, Shares Issued Common Stock, par value (usd per share) Common Stock, Par or Stated Value Per Share Common Stock, shares authorized Common Stock, Shares Authorized Common Stock, shares issued Common Stock, Shares, Issued Common Stock, shares outstanding Common Stock, Shares, Outstanding Treasury Stock, shares Treasury Stock, Shares Condensed Financial Information of Parent Company Only Disclosure [Abstract] Condensed Consolidating Balance Sheet Condensed Consolidating Balance Sheet Supplemental Guarantor Information [Table Text Block] Condensed Consolidating Balance Sheet Supplemental Guarantor Information [Table Text Block] Condensed Consolidating Statement Of Operations Condensed Consolidating Statement Of Operations Supplemental Guarantor Information [Table Text Block] Condensed Consolidating Statement Of Operations Supplemental Guarantor Information [Table Text Block] Condensed Consolidating Statement Of Comprehensive Income (Loss) Schedule of Comprehensive Income (Loss) [Table Text Block] Condensed Consolidating Statement Of Cash Flows Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] Schedule Of Segment Reporting Information By Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Statement, Geographical [Axis] Geographical [Axis] Segment, Geographical [Domain] Segment, Geographical [Domain] United States [Member] UNITED STATES International [Member] International [Member] International [Member] Segment Reporting Information, by Segment [Axis] Business Segments [Axis] Reporting Segment [Domain] Segment [Domain] Endo Pharmaceuticals [Member] Endo Pharmaceuticals [Member] Endo Pharmaceuticals [Member] Qualitest [Member] Qualitest [Member] Qualitest [Member] Healthtronics [Member] Healthtronics [Member] Healthtronics [Member] Corporate Unallocated [Member] Corporate Unallocated [Member] Corporate Unallocated [Member] Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Number of reportable segments Number of Reportable Segments Barriers to market entry Segment Reporting Information, Barriers To Market Entry Segment Reporting Information, Barriers To Market Entry Concentration risk percentage Concentration Risk, Percentage Total consolidated net revenues to external customers Revenues Total consolidated adjusted income before income tax Adjusted Income (Loss) Before Income Tax Adjusted income (loss) before income tax. From July 15, 2015 To And Including July 14, 2016 [Member] From July Fifteen Two Thousand Fifteen To And Including July Fourteen Two Thousand Sixteen [Member] From July Fifteen Two Thousand Fifteen To And Including July Fourteen Two Thousand Sixteen [Member]. From July 15, 2016 To And Including July 14, 2017 [Member] From July Fifteen Two Thousand Sixteen To And Including July Fourteen Two Thousand Seventeen [Member] From July Fifteen Two Thousand Sixteen To And Including July Fourteen Two Thousand Seventeen [Member]. From July 15, 2017 And Thereafter [Member] From July Fifteen Two Thousand Seventeen And Thereafter [Member] From July Fifteen Two Thousand Seventeen And Thereafter [Member]. From December 15, 2015 To And Including December 14, 2016 [Member] From December Fifteen Two Thousand Fifteen To And Including December Fourteen Two Thousand Sixteen [Member] From December Fifteen Two Thousand Fifteen To And Including December Fourteen Two Thousand Sixteen [Member] From December 15, 2016 To And Including December 14, 2017 [Member] From December Fifteen Two Thousand Sixteen To And Including December Fourteen Two Thousand Seventeen [Member] From December Fifteen Two Thousand Sixteen To And Including December Fourteen Two Thousand Seventeen [Member] From December 15, 2017 To And Including December 14, 2018 [Member] From December Fifteen Two Thousand Seventeen To And Including December Fourteen Two Thousand Eighteen [Member] From December Fifteen Two Thousand Seventeen To And Including December Fourteen Two Thousand Eighteen [Member]. From December 15, 2018 And Thereafter [Member] From December Fifteen Two Thousand Eighteen And Thereafter [Member] From December Fifteen Two Thousand Eighteen And Thereafter [Member]. From July 15, 2016 To And Including July 14, 2017 [Member] From July 15, 2017 To And Including July 14, 2018 [Member] From July Fifteen Two Thousand Seventeen To And Including July Fourteen Two Thousand Eighteen [Member] From July Fifteen Two Thousand Seventeen To And Including July Fourteen Two Thousand Eighteen [Member] From July 15, 2018 To And Including July 14, 2019 [Member] From July Fifteen Two Thousand Eighteen To And Including July Fourteen Two Thousand Nineteen [Member] From July Fifteen Two Thousand Eighteen To And Including July Fourteen Two Thousand Nineteen [Member]. From July 15, 2019 And Thereafter [Member] From July Fiftee From July Fifteen Two Thousand Nineteen And Thereafter Member N Two Thousand Nineteen And Thereafter [Member] From July Fifteen Two Thousand Nineteen And Thereafter [Member]. 7.25% Senior Notes Due 2022 [Member] Seven Point Two Five Percent Senior Notes Due Two Thousand Twenty Two [Member] Seven Point Two Five Percent Senior Notes Due Two Thousand Twenty Two [Member]. 7.00% Senior Notes Due 2020 [Member] Seven Point Zero Zero Percent Senior Notes Due Two Thousand Twenty [Member] Seven Point Zero Zero Percent Senior Notes Due Two Thousand Twenty [Member]. 7.00% Senior Notes Due 2019 [Member] Seven Point Zero Zero Percent Senior Notes Due Two Thousand Nineteen [Member] Seven Point Zero Zero Percent Senior Notes Due Two Thousand Nineteen [Member]. Payment Dates (between indicated dates) Redemption Payment Dates Redemption Payment Dates Redemption Percentage Redemption Percentage Percentage of principal amount Percentage Of Principal Amount Percentage Of Principal Amount Outstanding, Number of Shares, January 1, 2012 Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Granted, Number of Shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures Exercised, Number of Shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Forfeited, Number of Shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Expired, Number of Shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period Outstanding, Number of Shares, June 30, 2012 Vested and expected to vest, June 30, 2012, Number of Shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Exercisable, June 30, 2012, Number of Shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Outstanding, Weighted Average Exercise Price, January 1, 2012 Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Granted, Weighted Average Exercise Price Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Exercised, Weighted Average Exercise Price Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Forfeited, Weighted Average Exercise Price Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Expired, Weighted Average Exercise Price Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Outstanding, Weighted Average Exercise Price, June 30, 2012 Vested and expected to vest, June 30, 2012, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Exercisable, June 30, 2012, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Outstanding, June 30, 2012, Weighted Average Remaining Contractual Term Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Vested and expected to vest, June 30, 2012, Weighted Average Remaining Contractual Term Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Exercisable, June 30, 2012, Weighted Average Remaining Contractual Term Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Outstanding, June 30, 2012, Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Vested and expected to vest, June 30, 2012, Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Exercisable, June 30, 2012, Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Goodwill and other intangibles Goodwill and Intangible Assets Disclosure [Text Block] Schedule of Business Acquisitions by Acquisition, Equity Interest Issued or Issuable [Table] Schedule of Business Acquisitions by Acquisition, Equity Interest Issued or Issuable [Table] As Initially Reported [Member] As Initially Reported [Member] As Initially Reported [Member] Measurement period adjustments [Member] Measurement Period Adjustments [Member] Measurement Period Adjustments [Member] Business Acquisition, Equity Interests Issued or Issuable [Line Items] Business Acquisition, Equity Interests Issued or Issuable [Line Items] Cash and cash equivalents Business Acquisition, Purchase Price Allocation, Current Assets, Cash and Cash Equivalents Commercial paper Commercial Paper, at Carrying Value Accounts receivable Business Acquisition, Purchase Price Allocation, Current Assets, Receivables Other receivables Business Acquisition Purchase Price Allocation Current Assets Receivables Other Business Acquisition Purchase Price Allocation Current Assets Receivables Other Inventories Business Acquisition, Purchase Price Allocation, Current Assets, Inventory Prepaid expenses and other current assets Business Acquisition, Purchase Price Allocation, Current Assets, Prepaid Expense and Other Assets Income taxes receivable Business Acquisition Purchase Price Allocation Income Taxes Receivable Business acquisition purchase price allocation income taxes receivable. Deferred income taxes Business Acquisition Purchase Price Allocation Deferred Income Taxes Assets Business Acquisition Purchase Price Allocation Deferred Income Taxes Assets Property, plant and equipment Business Acquisition, Purchase Price Allocation, Property, Plant and Equipment Other intangible assets Business Acquisition, Purchase Price Allocation, Intangible Assets Not Amortizable Other assets Business Acquisition, Purchase Price Allocation, Other Noncurrent Assets Total identifiable assets Business Acquisition, Purchase Price Allocation, Assets Acquired Accounts payable Business Acquisition, Purchase Price Allocation, Current Liabilities, Accounts Payable Accrued expenses Business Acquisition, Purchase Price Allocation, Current Liabilities, Accrued Liabilities Deferred income taxes Business Acquisition Purchase Price Allocation Deferred Income Taxes Liabilities Business Acquisition Purchase Price Allocation Deferred Income Taxes Liabilities Long-term debt Business Acquisition, Purchase Price Allocation, Noncurrent Liabilities, Long-term Debt Other liabilities Business Acquisition, Purchase Price Allocation, Other Noncurrent Liabilities Total liabilities assumed Business Acquisition, Purchase Price Allocation, Liabilities Assumed Net identifiable assets acquired Business Acquisition, Purchase Price Allocation, Assets Acquired (Liabilities Assumed), Net Goodwill Business Acquisition, Purchase Price Allocation, Goodwill Amount Net assets acquired Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Less Noncontrolling Interest Supplemental Guarantor Information Condensed Financial Information of Parent Company Only Disclosure [Text Block] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Net (loss) income attributable to Endo Pharmaceuticals Holdings Inc. common stockholders Net Income (Loss) Attributable to Parent For basic per share data-weighted average shares Weighted Average Number of Shares Outstanding, Basic Dilutive effect of common stock equivalents Incremental Common Shares Attributable to Share-based Payment Arrangements Incremental Common Shares Attributable to Equity Unit Purchase Agreements Incremental Common Shares Attributable to Equity Unit Purchase Agreements Dilutive effect of 1.75% Convertible Senior Subordinated Notes and warrants Dilutive Effect Of One Point Seven Five Percentage Of Convertible Senior Subordinated Notes Dilutive Effect Of One Point Seven Five Percentage Of Convertible Senior Subordinated Notes For diluted per share data-weighted average shares Weighted Average Number of Shares Outstanding, Diluted Basic net (loss) income per share attributable to Endo Health Solutions Inc Earnings Per Share, Basic Diluted net (loss) income per share attributable to Endo Health Solutions Inc Earnings Per Share, Diluted Acquisition-related contingent consideration - short-term [Member] Acquisition Related Contingent Consideration Short Term [Member] Acquisition Related Contingent Consideration-Short Term [Member] Acquisition-related contingent consideration - long-term [Member] Acquisition Related Contingent Consideration Long Term [Member] Acquisition-Related Contingent Consideration-Long Term [Member] Derivative instruments [Member] Derivative [Member] Quoted prices In active markets for identical assets (Level 1) [Member] Fair Value, Inputs, Level 1 [Member] Significant other observable inputs (Level 2) [Member] Fair Value, Inputs, Level 2 [Member] Fair value of financial assets measured on recurring basis Assets, Fair Value Disclosure, Recurring Fair value of financial liabilities measured on recurring basis Liabilities, Fair Value Disclosure, Recurring Acquisition-related contingent consideration - short-term Acquisition-Related Contingent Consideration - Short-Term Acquisition-related contingent consideration - short-term Acquisition-related contingent consideration - long-term Acquisition-Related Contingent Consideration - Long-Term Acquisition-related contingent consideration - long-term Carrying amounts and estimated fair values of other financial instruments Schedule of Carrying Amounts and Estimated Fair Values of Other Financial Instruments [Text Block] Schedule of Carrying Amounts and Estimated Fair Values of Other Financial Instruments [Text Block] Financial assets and liabilities measured at fair value on recurring basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Financial assets measured at fair value on recurring basis using significant unobservable inputs Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Financial liabilities measured at fair value on recurring basis using significant unobservable inputs Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Summary of available-for-sale securities Available-for-sale Securities [Table Text Block] Schedule of financial assets measured at fair value on a nonrecurring basis Fair Value Measurements, Nonrecurring [Table Text Block] Schedule of changes in the carrying amount of goodwill Schedule of Goodwill [Table Text Block] Schedule of other intangible assets Schedule Of Other Intangible Assets [Table Text Block] Schedule of other intangible assets table text block Schedule of changes in gross carrying amount of other intangible assets Schedule Of Changes In Gross Carrying Amount Of Other Intangible Assets [Table Text Block] Schedule Of Changes In Gross Carrying Amount Of Other Intangible Assets [Table Text Block] Schedule of estimated amortization of intangibles Schedule of Expected Amortization Expense [Table Text Block] Revenue Business Acquisition, Pro Forma Revenue Net income attributable to Endo Health Solutions Inc. Business Acquisition, Pro Forma Net Income (Loss) Basic net income per share (usd per share) Business Acquisition, Pro Forma Earnings Per Share, Basic Diluted net income per share (usd per share) Business Acquisition, Pro Forma Earnings Per Share, Diluted Schedule of Entity-Wide Revenue by Major Customers, by Reporting Segments [Table] Schedule of Revenue by Major Customers, by Reporting Segments [Table] Depreciation expense Depreciation Amortization expense Amortization Schedule of Deferred Compensation Arrangement with Individual, Share-based Payments [Table] Schedule of Deferred Compensation Arrangement with Individual, Share-based Payments [Table] Award Type [Axis] Award Type [Axis] Award Type [Domain] Award Type [Domain] Performance stock units [Member] Performance Stock Units [Member] Performance Stock Units [Member] Restricted stock [Member] Restricted Stock [Member] Restricted stock units (RSUs) [Member] Restricted Stock Units (RSUs) [Member] Non vested stock options [Member] Non Vested Stock Options [Member] Non Vested Stock Options [Member] Non vested restricted stock units [Member] Non Vested Restricted Stock Units [Member] Non Vested Restricted Stock Units [Member] Non vested restricted stock [Member] Non Vested Restricted Stock [Member] Non Vested Restricted Stock [Member] Plan Name [Axis] Plan Name [Axis] Plan Name [Domain] Plan Name [Domain] 2000 Stock incentive plan [Member] Two Thousand Stock Incentive Plan [Member] Two Thousand Stock Incentive Plan [Member] 2004 Stock incentive plan [Member] Two Thousand Four Stock Incentive Plan [Member] Two Thousand Four Stock Incentive Plan [Member] 2007 Stock incentive plan [Member] Two Thousand Seven Stock Incentive Plan [Member] Two Thousand Seven Stock Incentive Plan [Member] 2010 Stock incentive plan [Member] Two Thousand Ten Stock Incentive Plan [Member] Two Thousand Ten Stock Incentive Plan [Member] 2005 AMS stock incentive plan [Member] Two Thousand Five Ams Stock Incentive Plan [Member] Two Thousand Five AMS Stock Incentive Plan [Member] 2008 Share repurchase program [Member] 2008 Share Repurchase Program [Member] 2008 Share Repurchase Program [Member] 2012 Share repurchase program [Member] 2012 Share Repurchase Program [Member] 2012 Share Repurchase Program [Member] Employee stock purchase plan [Member] Employee Stock Purchase Plan [Member] Employee Stock Purchase Plan [Member] Shareholders Equity [Line Items] Shareholders Equity [Line Items] Shareholders Equity [Line Items] Maximum number of shares reserved for issuance Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Maximum number of shares per participant Share Based Compensation Arrangement by Share-based Payment Award Per Participant Maximum Share Based Compensation Arrangement by Share-based Payment Award Per Participant Maximum Shares reserved for future issuance Common Stock, Capital Shares Reserved for Future Issuance Number of shares issued to be settled in Company's stock Share-Based Compensation Arrangement By Share-Based Payment Award, Equity other than options, Number of Shares Issued to Be Settled in Stock Share-based compensation arrangement by share-based payment award, equity other than options, number of shares issued to be settled in stock. Number of shares exceeding total number of shares of Company stock subject to awards awarded to a participant Number Of Shares Exceeding Total Number Of Shares Of Company Stock Subject to Awards Awarded To A Participant Number of shares exceeding total number of shares of company stock subject to awards awarded to a participant. Stock-based compensation expense Allocated Share-based Compensation Expense Unrecognized compensation cost Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized Assumptions related to volatility, dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Total intrinsic value of options exercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Total Intrinsic Value Weighted-average grant date fair value of stock options, per option Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted average remaining requisite service period of non-vested stock awards, years Weighted Average Remaining Requisite Service Period Of Non Vested Stock Options Weighted Average Remaining Requisite Service Period Of Non Vested Stock Options Weighted average remaining requisite service period of non-vested restricted stock units, years Weighted Average Remaining Requisite Service Period Of Non Vested Restricted Stock Units Weighted Average Remaining Requisite Service Period Of Non Vested Restricted Stock Units Weighted-average grant date fair value of restricted stock units, per unit Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Performance cycle, in years Share-based Compensation Arrangement by Share-based Payment Award, Performance Cycle Period Share-based Compensation Arrangement by Share-based Payment Award, Performance Cycle Period Conversion of performance stock units to common shares Stock Issued During Period, Shares, Conversion of Units Cumulative revenue performance, in years Cumulative revenue performance period Cumulative revenue performance period. Target revenue period, in years Target Revenue Period Target Revenue Period Restricted stock units and performance shares granted to employees Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Weighted-average period over which unrecognized compensation costs will be recognized, years Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition Stock Repurchase Program, Authorized Amount Stock Repurchase Program, Authorized Amount Share repurchase plan extension period Treasury Stock, Share Repurchase Plan Extension Period Treasury Stock, Share Repurchase Plan Extension Period Repurchase of common stock, shares Treasury Stock, Shares, Acquired Repurchase of common stock, value Percentage of contribution by the employees Percentage Of Contribution By The Employees Percentage of contribution by the employees Non-qualified stock options granted to executive officer Extended expiry date of share repurchase program Extended Expiry Date Of Share Repurchase Program Extended Expiry Date Of Share Repurchase Program Percentage of price per common stock Percentage Of Price Per Common Stock Percentage Of Price Per Common Stock Numerator to calculate maximum number of shares a participant may purchase in a calendar year Share-Based Compensation, ESPP Contribution, Amount Numerator Numerator used to calculate the ESPP contribution Common shares outstanding Percentage of common shares outstanding Percentage Of Common Shares Outstanding Percentage of common shares outstanding Shares issued pursuant to the ESPP Stock Issued During Period, Shares, Treasury Stock Reissued Proceeds from issuance of treasury stock Lender Name [Axis] 1.75% Convertible Senior Subordinated Notes Due 2015 [Member] One Point Seven Five Percent Convertible Senior Subordinated Notes Due Thousand Fifteen [Member] One Point Seven Five Percent Convertible Senior Subordinated Notes Due Thousand Fifteen [Member]. Term Loan A Facility Due 2016 [Member] Term Loan Facility Due Two Thousand Sixteen [Member] Term Loan A Facility Due Two Thousand Sixteen [Member] Term Loan B Facility Due 2018 [Member] Term Loan B Facility Due Two Thousand Eighteen [Member] Term Loan B Facility Due Two Thousand Eighteen [Member] Long Term Debt, Term Long Term Debt, Term Long Term Debt, Term Convertible note, gross Convertible Note Gross Convertible note gross. Unamortized discount Debt Instrument, Unamortized Discount Convertible debt Convertible Debt Senior notes, Gross Long-term Debt, Gross Unamortized initial purchaser's discount Unamortized Initial Purchaser's Discount And Debt Issuance Costs Unamortized initial Purchaser's discount and debt issuance costs. Senior notes Senior Notes Face value of debt instrument Debt Instrument, Face Amount Other long-term debt Other Long-term Debt Total long-term debt, net Long-term Debt Total long-term debt, less current portion, net Notes, maturity year Line of Credit Facility, Expiration Date Line of Credit Facility, Expiration Date Acquisitions Business Combination Disclosure [Text Block] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table] Fair Value Measurements, Recurring and Nonrecurring [Table] Business Segments [Axis] Sanctura Xr [Member] Sanctura Xr [Member] Sanctura XR member. AMS IPR&D [Member] AMS IPR&D [Member] AMS IPR&D [Member] Unclassified indefinite lived intangible assets [Member] Fair Value, Hierarchy [Axis] Fair Value, Measurements, Fair Value Hierarchy [Domain] Scenario [Axis] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Intangible assets Asset impairment charges Loss related to litigation settlement Initial Estimate of Loss Related to Litigation Settlement Initial Estimate of Loss Related to Litigation Settlement Change in estimate of litigation liability Fair value measurements Fair Value Disclosures [Text Block] Components Of Cost Of Revenues Schedule Of Cost Of Revenue [Table Text Block] Schedule Of Cost Of Revenue [Table Text Block] Statement [Table] Statement [Table] Endo Health Solutions Inc. [Member] Parent Company [Member] Guarantor Subsidiaries [Member] Guarantor Subsidiaries [Member] Non-Guarantor Subsidiaries [Member] Non-Guarantor Subsidiaries [Member] Eliminations [Member] Consolidation, Eliminations [Member] Statement [Line Items] Statement [Line Items] Accounts receivable, net Inventories, net Total current assets INTERCOMPANY RECEIVABLES Related Party Transaction, Due from (to) Related Party, Noncurrent INVESTMENT IN SUBSIDIARIES Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures TOTAL ASSETS Current portion of long-term debt Total current liabilities INTERCOMPANY PAYABLES Intercompany Payables Intercompany payables. Preferred Stock Common Stock Retained earnings (deficit) Accumulated other comprehensive (loss) income Treasury stock Total Endo Health Solutions Inc. stockholders' equity Total stockholders' equity TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY Inventories Inventory Disclosure [Text Block] Net cash (used in) provided by operating activities Purchases of property, plant and equipment Proceeds from sale of property, plant and equipment Other investments Payments for (Proceeds from) Other Investing Activities License fees Proceeds from License Fees Received Net cash used in investing activities Proceeds from issuance of 2019 and 2022 Notes Proceeds from Issuance of Long-term Debt Principal payments on Term Loans, net Payment on AMS Convertible Notes Proceeds from (Repayments of) Notes Payable Purchase of common stock Intercompany activity Intercompany Financing Intercompany Financing Net cash used in financing activities NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS Goodwill [Roll Forward] Goodwill [Roll Forward] Balance at December 31, 2011 Goodwill acquired during the period Goodwill, Acquired During Period Measurement period adjustments Goodwill Measurement Period Adjustments Goodwill measurement period adjustments. Goodwill, Other Changes Goodwill, Other Changes Balance at September 30, 2012 Schedule of Goodwill And Other Intangibles [Table] Schedule of Goodwill And Other Intangibles [Table] Schedule of Goodwill and Other Intangibles [Table]. Licenses [Member] Licensing Agreements [Member] Other definite-lived intangibles [Member] Other Intangible Assets [Member] Other Intangible Assets [Line Items] Other Intangible Assets [Line Items] Other Intangible Assets [Line Items] Indefinite-lived intangibles Indefinite-Lived Intangible Assets (Excluding Goodwill) Licenses Finite-Lived License Agreements, Gross Customer relationships Finite-Lived Customer Relationships, Gross Tradenames Finite-Lived Trade Names, Gross Developed technology Finite-Lived Computer Software, Gross Other Other Finite-Lived Intangible Assets, Gross Less accumulated amortization Finite-Lived Intangible Assets, Accumulated Amortization Total definite-lived intangibles, net Finite-Lived Intangible Assets, Net Other intangibles, net Other Intangible Assets, Net Weighted average life, in years Finite-Lived Intangible Asset, Useful Life Organization, Consolidation and Presentation of Financial Statements [Abstract] Basis of presentation Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Total consolidated adjusted income before income tax Upfront and milestone payments to partners Upfront And Milestone Payments To Partners Upfront and milestone payments to partners. Asset impairment charges Acquisition-related and integration items, net Acquisition Costs, Period Cost Seperation benefits and other cost reduction initiatives Cost Reduction Initiatives Cost Reduction Initiatives Amortization of intangible assets Amortization of Intangible Assets Inventory step-up Inventory Step Up Inventory Step Up Non-cash interest expense Non-Cash Interest Expense Non-cash interest expense. Loss on extinguishment of debt Gains (Losses) on Extinguishment of Debt Accrual for payment to Impax related to sales of Opana ER Accrual for payment related to purchase of branded pharmaceuticals Accrual for payment related to purchase of branded pharmaceuticals Litigation-related contingencies Other Non-operating Income (Expense), Nonrecurring Other Non-operating Income (Expense), Nonrecurring Other Non-operating Income (Expense), Nonrecurring Other Nonoperating Income (Expense) Other Nonoperating Income (Expense) (LOSS) INCOME BEFORE INCOME TAX Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest Schedule Of Stockholders' Equity [Table] Schedule Of Stockholders' Equity [Table] Schedule Of Stockholders' Equity [Table] Statement, Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Endo Health Solutions Inc [Member] Stockholders' Equity, Total [Member] Noncontrolling Interests [Member] Noncontrolling Interest [Member] Stockholders' Equity [Line Items] Stockholders' Equity [Line Items] Stockholders' Equity [Line Items] Stockholders' equity at January 1, 2012 Net (loss) income Other comprehensive income Other Comprehensive Income (Loss), Net of Tax Compensation related to stock-based awards Dividends, Share-based Compensation, Cash Exercise of options Stock Issued During Period, Value, Stock Options Exercised Common stock purchased, net of common stock issued from treasury Treasury Stock, Value Acquired Net of Value Issued, Cost Method Treasury Stock, Value Acquired Net of Value Issued, Cost Method Distributions to noncontrolling interests Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders Buy-out of noncontrolling interests, net of contributions Stockholders Equity, Period Decrease, Buy-out of Noncontrolling Interests, Net of Contributions Stockholders Equity, Period Decrease, Buy-out of Noncontrolling Interests, Net of Contributions Other Stockholders' Equity, Other Stockholders' equity at June 30, 2012 Document And Entity Information [Abstract] Document and Entity Information [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Trading Symbol Trading Symbol Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Restricted Stock Units [Line Items] Restricted Stock Units [Line Items] Restricted Stock Units [Line Items] Outstanding, Number of Shares, January 1, 2012 Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Granted, Number of Shares Forfeited, Number of Shares Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Vested, Number of Shares Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Outstanding, Number of Shares, June 30, 2012 Vested and expected to vest, June 30, 2012, Number of Shares Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Outstanding, Aggregate Intrinsic Value, June 30, 2012 Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Aggregate Intrinsic Value Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Aggregate Intrinsic Value Vested and expected to vest, June 30, 2012, Aggregate Intrinsic Value Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Aggregate Intrinsic Value Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Aggregate Intrinsic Value Income Taxes Income Tax Disclosure [Text Block] Income Statement [Abstract] REVENUES: Revenues [Abstract] Net pharmaceutical product sales Revenue, Net Devices revenues Sales Revenue, Goods, Net Service and other revenues Other Revenue, Net TOTAL REVENUES COSTS AND EXPENSES: Costs and Expenses [Abstract] Cost of revenues Selling, general and administrative Selling, General and Administrative Expense Research and development Research and Development Expense Litigation settlement expense Litigation-related contingencies Asset impairment charges Acquisition-related items, net OPERATING (LOSS) INCOME Operating Income (Loss) INTEREST EXPENSE, NET Interest Income (Expense), Net LOSS ON EXTINGUISHMENT OF DEBT OTHER EXPENSE, NET INCOME TAX CONSOLIDATED NET (LOSS) INCOME Less: Net income attributable to noncontrolling interests Net Income (Loss) Attributable to Noncontrolling Interest NET INCOME ATTRIBUTABLE TO ENDO HEALTH SOLUTIONS INC. NET (LOSS) INCOME PER SHARE ATTRIBUTABLE TO ENDO HEALTH SOLUTIONS INC.: Basic (usd per share) Diluted (usd per share) WEIGHTED AVERAGE SHARES: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Basic Diluted Schedule of Short-term Debt [Table] Schedule of Short-term Debt [Table] 1.75% Convertible Senior Subordinated Notes Due April 15, 2015 [Member] One Point Seven Five Percent Senior Subordinated Notes Due April Fifteen Two Thousand And Fifteen [Member] One Point Seven Five Percent Senior Subordinated Notes Due April Fifteen Two Thousand And Fifteen [Member] Net (Loss) Income Per Share [Line Items] Net (Loss) Income Per Share [Line Items] Net (Loss) Income Per Share [Line Items] Convertible Notes, maturity date Debt Instrument, Maturity Date Convertible Notes, convertible amount per share Debt Instrument, Convertible, Conversion Price Number of shares that could potentially be anti-dilutive if warrants were exercised Debt Conversion, Converted Instrument, Shares Issued TOTAL REVENUES Asset impairment charges Impairment of Intangible Assets (Excluding Goodwill) OPERATING (LOSS) INCOME LOSS ON EXTINGUISHMENT OF DEBT OTHER EXPENSE (INCOME), NET (LOSS) INCOME BEFORE INCOME TAX EQUITY FROM EARNINGS (LOSS) IN SUBSIDIARIES Income (Loss) from Equity Method Investments NET INCOME ATTRIBUTABLE TO ENDO HEALTH SOLUTIONS INC. Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Business Acquisition [Line Items] Business Acquisition [Line Items] Schedule of fair values of the assets acquired and liabilities assumed at the acquisition date Schedule Of Fair Values Of the Assets Acquired And Liabilities Assumed At The Acquisition Date [Table Text block] Schedule Of Fair Values Of the Assets Acquired And Liabilities Assumed At The Acquisition Date [Table Text block] Schedule of valuation of the intangible assets acquired and related amortization periods Schedule Of Valuation Of Intangible Assets Acquired And Related Amortization Periods [Table Text Block] Schedule Of Valuation Of Intangible Assets Acquired And Related Amortization Periods [Table Text Block] Schedule of acquisition-related items in the accompanying consolidated statements of operations Schedule of Acquisition Related Expenses [Table Text Block] Schedule Of Acquisition Related Expenses [Table Text Block] Schedule of pro forma consolidated results Business Acquisition, Pro Forma Information [Table Text Block] License And Collaboration Agreements [Abstract] License and Collaboration Agreements Abstract License and collaboration agreements License And Collaboration Agreements [Text Block] License And Collaboration Agreements [Text Block] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Duration of Loss Position [Axis] Duration of Loss Position [Axis] Duration of Loss Position [Axis] Duration of Loss Position [Domain] Duration of Loss Position [Domain] [Domain] for Duration of Loss Position [Axis] Less than tweleve months [Member] Less Than Tweleve Months [Member] Less Than Tweleve Months [Member] More than tweleve months [Member] More Than Tweleve Months [Member] More Than Tweleve Months [Member] Balance Sheet Location [Axis] Balance Sheet Location [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Products and Services [Axis] Products and Services [Axis] Product and Service, Name [Domain]